Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsNew data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.
Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.
Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.
High Rates of Overactive Bladder Found in Women With Fibromyalgia
Advanced Cardiovascular-Kidney-Metabolic Syndrome Increases Sarcopenia Risk
FDA Grants Breakthrough Device Designation to Holly Implantable Dialysis System
1.
June 20, 2023, Health Bulletin No. 12.
2.
An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.
3.
Dense breasts: What it means and what women can do about screening
4.
Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.
5.
Smarter targeted radiotherapy just as effective for low-risk breast cancer and reduces risk of side effects
1.
The Importance of Having a Quick and Effective Heparin Antidote
2.
Unlocking the Secrets of Leukemic Stem Cells: A Path to Better Blood Cancer Treatments
3.
Angina Haemorrhagica Bullosa: What You Need to Know
4.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
5.
Case Study: Personalized Medicine Based on Genetic Profiling in Oncology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation